Candel Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Candel Therapeutics sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Candel Therapeutics: 13 sponsored US clinical trials, 2 recruiting.

Candel Therapeutics sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.

Top-decile sponsor footprint

Candel Therapeutics ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

NCT07660094
RECRUITING Phase 2

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000
ACTIVE NOT RECRUITING Phase 2

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

NCT04495153
ACTIVE NOT RECRUITING Phase 2

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
ACTIVE NOT RECRUITING Phase 2

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

NCT02446093
ACTIVE NOT RECRUITING Phase 3

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

NCT01436968
COMPLETED Phase 1

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

NCT03576612
COMPLETED Phase 1

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

NCT03131037
COMPLETED Phase 1

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

NCT01997190
COMPLETED Phase 1

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

NCT00634231
COMPLETED Phase 1

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612
COMPLETED Phase 2

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

NCT00589875
COMPLETED Phase 1

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas

NCT00751270

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 5
Phase 3 2

Therapeutic Areas

Prostate Cancer 2
Prostate Cancer Patients Treated by Radiotherapy 1
Borderline Resectable Pancreatic Adenocarcinoma 1
Prostate Cancer (Adenocarcinoma) 1
Non-Small Cell Lung Cancer 1

What is open in the Candel Therapeutics pipeline

2 recruiting of 13 indexed (15% open); 7 completed (54%).

Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Candel Therapeutics: open-pipeline peers nationwide

Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Candel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%5%10%15%20% Total trials Recruiting share Candel TherapeuticsAdaptimmuneAgennixAkili Interactive LabsAlumisArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Candel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Candel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Candel Therapeutics page

13 registered trials is a research-attention snapshot, not an endorsement of Candel Therapeutics or any single study.

  • 2 of Candel Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Candel Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Candel Therapeutics pipeline card: 13 registered trials from official public datasets.Report a data error.